Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC

A Bois, J Sehouli, B Lund, F Joly, J Huober, TS Jensen, E Levy, V Heilmann, K Boman, AC Hardy-bessard, A Burges, J Mäenpää

Research output: Contribution to journalArticleScientificpeer-review

Original languageUndefined/Unknown
Pages (from-to)224-225
JournalInt J Gynecol Cancer
Issue numberS3
Publication statusPublished - 2005
Publication typeA1 Journal article-refereed

Cite this